Pathogenic KDM5B variants in the context of developmental disorders

被引:3
|
作者
Harrington, Jack [1 ]
Wheway, Gabrielle [2 ]
Willaime-Morawek, Sandrine [3 ]
Gibson, Jane [1 ]
Walters, Zoe S. [1 ]
机构
[1] Univ Southampton, Fac Med, Sch Canc Sci, Southampton SO16 6YD, England
[2] Univ Southampton, Fac Med, Sch Human Dev & Hlth, Southampton SO16 6YD, England
[3] Univ Southampton, Fac Med, Clin Neurosci, Southampton SO16 6YD, England
关键词
Epigenetics; Histone modifying enzymes; KDM5B; Developmental disorders; AUTISM SPECTRUM DISORDERS; TRANSCRIPTIONAL REPRESSION; INTELLECTUAL DISABILITY; HISTONE MODIFICATIONS; SELF-RENEWAL; KDM5B; MUTATIONS; ACID; H3K4; DEMETHYLATION;
D O I
10.1016/j.bbagrm.2022.194848
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Histone modifying enzymes are involved in the posttranslational modification of histones and the epigenetic control of gene expression. They play a critical role in normal development, and there is increasing evidence of their role in developmental disorders (DDs). DDs are a group of chronic, severe conditions that impact the physical, intellectual, language and/or behavioral development of an individual. There are very few treatment options available for DDs such that these are conditions with significant unmet clinical need. Recessive variants in the gene encoding histone modifying enzyme KDM5B are associated with a DD characterized by develop-mental delay, facial dysmorphism and camptodactyly. KDM5B is responsible for the demethylation of lysine 4 on the amino tail of histone 3 and plays a vital role in normal development and regulating cell differentiation. This review explores the literature on KDM5B and what is currently known about its roles in development and developmental disorders.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Molecular architecture of the Jumonji C family histone demethylase KDM5B
    Jerzy Dorosz
    Line Hyltoft Kristensen
    Nanda G. Aduri
    Osman Mirza
    Rikke Lousen
    Saskia Bucciarelli
    Ved Mehta
    Selene Sellés-Baiget
    Sara Marie Øie Solbak
    Anders Bach
    Pablo Mesa
    Pablo Alcon Hernandez
    Guillermo Montoya
    Tam T. T. N. Nguyen
    Kasper D. Rand
    Thomas Boesen
    Michael Gajhede
    Scientific Reports, 9
  • [22] Development of 8-pyridopyrimidinone-based covalent inhibitors of KDM5B
    Wright, Miranda
    Vazquez-Rodriguez, Saleta
    Brennan, Paul
    Kawamura, Akane
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2018, 256
  • [23] Molecular architecture of the Jumonji C family histone demethylase KDM5B
    Dorosz, Jerzy
    Kristensen, Line Hyltoft
    Aduri, Nanda G.
    Mirza, Osman
    Lousen, Rikke
    Bucciarelli, Saskia
    Mehta, Ved
    Selles-Baiget, Selene
    Solbak, Sara Marie Oie
    Bach, Anders
    Mesa, Pablo
    Hernandez, Pablo Alcon
    Montoya, Guillermo
    Nguyen, Tam T. T. N.
    Rand, Kasper D.
    Boesens, Thomas
    Gajhede, Michael
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [24] Lysine demethylase 5B (KDM5B): A key regulator of cancer drug resistance
    Cao, Yaquan
    Wu, Chunli
    Ma, Liying
    JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY, 2024, 38 (01)
  • [25] Structure and binding properties of a cameloid nanobody raised against KDM5B
    Wiuf, Andcrs
    Kristcnsen, Line Hyltoft
    Kristensen, Olc
    Dorosz, Jerzy
    Jensen, Jonas
    Gajhede, Michael
    ACTA CRYSTALLOGRAPHICA SECTION F-STRUCTURAL BIOLOGY COMMUNICATIONS, 2015, 71 : 1235 - 1241
  • [26] Structural analysis of human KDM5B guides histone demethylase inhibitor development
    Johansson, Catrine
    Velupillai, Srikannathasan
    Tumber, Anthony
    Szykowska, Aleksandra
    Hookway, Edward S.
    Nowak, Radoslaw P.
    Strain-Damerell, Claire
    Gileadi, Carina
    Philpott, Martin
    Burgess-Brown, Nicola
    Wu, Na
    Kopec, Jola
    Nuzzi, Andrea
    Steuber, Holger
    Egner, Ursula
    Badock, Volker
    Munro, Shonagh
    LaThangue, Nicholas B.
    Westaway, Sue
    Brown, Jack
    Athanasou, Nick
    Prinjha, Rab
    Brennan, Paul E.
    Oppermann, Udo
    NATURE CHEMICAL BIOLOGY, 2016, 12 (07) : 539 - +
  • [27] Structural analysis of human KDM5B guides histone demethylase inhibitor development
    Johansson C.
    Velupillai S.
    Tumber A.
    Szykowska A.
    Hookway E.S.
    Nowak R.P.
    Strain-Damerell C.
    Gileadi C.
    Philpott M.
    Burgess-Brown N.
    Wu N.
    Kopec J.
    Nuzzi A.
    Steuber H.
    Egner U.
    Badock V.
    Munro S.
    Lathangue N.B.
    Westaway S.
    Brown J.
    Athanasou N.
    Prinjha R.
    Brennan P.E.
    Oppermann U.
    Nature Chemical Biology, 2016, 12 (7) : 539 - 545
  • [28] Lysine demethylase 5B (KDM5B): A potential anti-cancer drug target
    Zheng, Yi-Chao
    Chang, Jiao
    Wang, Lin-Chen
    Ren, Hong-Mei
    Pang, Jing-Ru
    Liu, Hong-Min
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 161 : 131 - 140
  • [29] Studies on the Interaction of the Histone Demethylase KDM5B with Tricarboxylic Acid Cycle Intermediates
    Tarhonskaya, Hanna
    Nowak, Radoslaw P.
    Johansson, Catrine
    Szykowska, Aleksandra
    Tumber, Anthony
    Hancock, Rebecca L.
    Lang, Pauline
    Flashman, Emily
    Oppermann, Udo
    Schofield, Christopher J.
    Kawamura, Akane
    JOURNAL OF MOLECULAR BIOLOGY, 2017, 429 (19) : 2895 - 2906
  • [30] Connexin 26 is Down-Regulated by KDM5B in the Progression of Bladder Cancer
    Li, Xin
    Su, Yongping
    Pan, Jinhong
    Zhou, Zhansong
    Song, Bo
    Xiong, Enqing
    Chen, Zhiwen
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2013, 14 (04) : 7866 - 7879